Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
07:00am, Monday, 02'nd Feb 2026
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar ® (TLD-1433) in patients with Bacillus Calmette-Guér
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have entered into a collaborative clinical devel
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
04:39pm, Tuesday, 23'rd Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
05:00pm, Friday, 12'th Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
07:00am, Monday, 24'th Nov 2025
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering l
Theralase(R) Investor Conference Call Reminder
07:00am, Monday, 17'th Nov 2025
Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase®
Theralase Technologies (CVE:TLT) Shares Up 2.4% – Here’s What Happened
04:22am, Saturday, 01'st Nov 2025
Theralase Technologies Inc. (CVE: TLT - Get Free Report) shot up 2.4% on Friday. The stock traded as high as C$0.21 and last traded at C$0.21. 63,000 shares changed hands during trading, a decline of
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
07:00am, Wednesday, 24'th Sep 2025
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase ®" or the "Company"), a clinical stage pharmaceutical company pioneerin
Theralase(R) Extends Warrants
04:30pm, Friday, 29'th Aug 2025
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase ®" or the "Company"), a clinical stage pharmaceutical company pioneering
Theralase(R) Releases 2Q2025 Financial Statements
04:30pm, Tuesday, 26'th Aug 2025
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, ra
Theralase(R) Closes Non-Brokered Private Placement
07:00am, Monday, 28'th Jul 2025
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering lig
Theralase(R) Extends Warrants
04:30pm, Friday, 27'th Jun 2025
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase ®" or the "Company"), a clinical stage pharmaceutical company pioneering lig
Theralase(R) Closes Non-Brokered Private Placement
07:00am, Tuesday, 17'th Jun 2025
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering lig
Theralase Completes Annual General and Special Meeting
07:00am, Thursday, 12'th Jun 2025
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering li
